Amgen

Product sales were $9.54B of $10.05B in total revenues. Repatha, the largest brand, was 9.48% of revenue, and the other principal brands ranged from 2.86% for Imdelltra to 7.55% for Prolia. Non-principal products together were 16.88%, and other revenues, which the filing attributes to corporate partner revenue and royalty income, 5.14%.¹

AnalysisOur reading: with revenue spread across many mid-sized brands, the loss of protection on any one product removes a slice of revenue rather than its base. That is what lets the company absorb an expiry as large as the one on Prolia and Xgeva inside a growing year, and it limits how far any single pricing decision or trial result can move the total.

Operating cash flow was $4.0B against net income of $2.38B, a ratio of 1.69. A year earlier operating cash of $2.28B was 159.2% of net income of $1.43B. Capital spending of $513M took 12.8% of operating cash flow and 5.1% of revenue, leaving free cash flow of $3.49B, a margin of 34.7% against 20.8% a year earlier.¹

The filing calls operating cash its "primary recurring source of funds" and says the rise in operating cash for the first half reflects the final repatriation tax payment made in the same period last year and higher net income. Capital spending is going into new plants and expanded manufacturing capacity, and the filing says its U.S. manufacturing investments earned it relief from new tariffs on certain patented medicines for about three years.¹

AnalysisOur reading: cash runs ahead of reported profit partly because amortization of acquired product rights is a charge without a cash payment. As that charge declines, reported profit would tend to move closer to cash, so the ratio could narrow even if the business earns the same. Free cash flow is the measure the accounting effect does not reach.

The filing says product sales rose on volume: U.S. volume grew 9% and rest-of-world volume 8%. Blincyto grew 22.9% on volume growth of 16%, and Nplate 16.5% on volume growth of 13%. Krystexxa is the price-led exception, with net selling price up 23% and sales up 14.6%.¹

For the rest of the year the filing expects "volume growth from certain brands to be partially offset by net selling price declines", and it describes an industry subject to "cost containment measures and significant pricing pressures, resulting in net price declines".¹

AnalysisOur reading: when payers rather than the company decide what a medicine nets, growth built on more patients holds up better than growth built on price. A brand adding patients can absorb a negotiated cut and still expand; a brand growing on price is exposed at its next negotiation.

Enbrel's sales slipped 4.0% to $580M as its net selling price fell 22%, which the filing attributes to Medicare Part D price setting under the IRA from the start of the year and a larger share of sales through a federal discount program, partly offset by favorable changes in estimated sales deductions. Enbrel is 5.77% of revenue.¹

Otezla fell 20.6% to $491M on net price down 9% and volume down 6%, with generic competition in some European countries. Its Medicare set price takes effect next January, and the filing expects further net price declines from then. Otezla is 4.88% of revenue, and its acquired product rights were already partly written down after it was selected.¹

The filing says the IRA's price setting and Part D redesign have had an adverse effect whose impact "is expected to increase through the end of the decade", and that, depending on their growth and success, other medicines "may also be subject to selection" in a future cycle.¹

AnalysisOur reading: selection follows success, so the brands carrying today's growth are the natural candidates for later cycles. The exposure rises with the portfolio's best performers, and what matters is whether new launches arrive faster than the program reaches them.

The IRS proposes moving profits that Amgen allocated to its Puerto Rico entities back to the United States for earlier years. The consolidated Tax Court case has been tried and briefed, and the company expects a decision no earlier than late this year or early next. The IRS has reissued a similar proposed adjustment for later years, which the filing says "could have a material impact" if sustained in full, and has begun auditing the years after that.¹

The filing says substantially all of the benefit to its effective tax rate from foreign earnings comes from manufacturing locations including Singapore, Ireland and Puerto Rico. This quarter the effective rate was 14.2%, against 8.7% a year earlier, on a provision of $393M. Amgen says it firmly believes the IRS positions are without merit, but that the outcome "may result in payments substantially greater than amounts accrued".¹

AnalysisOur reading: the dispute goes to the low tax rate that turns operating profit into net income. An adverse ruling would show first in the notes and in cash, as a payment, before it touched revenue or margin, and it could bear on how the later years under audit are treated.

The FDA's drug center has proposed withdrawing approval of Tavneos, alleging new information indicating a lack of substantial evidence of effectiveness and untrue statements of material fact in the original application by ChemoCentryx, which Amgen acquired. Amgen requested a hearing and submitted real-world evidence and a blinded re-adjudication of trial data. If a hearing is not granted, the FDA may enter summary judgment and withdraw approval.¹

The FDA has also issued a safety communication about serious liver injury, including fatal cases, and the U.S. label was updated. The filing says its evaluation at quarter end showed the carrying value of the Tavneos product rights remains recoverable, but that future changes to its estimated cash flows could unfavorably affect that.¹

AnalysisOur reading: Tavneos is not a principal brand and its sales sit within other products, but the exposure lies in the balance sheet as much as in revenue. As with Otezla's write-down after its Medicare selection, a regulatory decision can reach reported profit through an impairment charge before it shows in sales.